This article is more than 5 years old. Information may no longer be current.

Orthocell to collaborate with DePuy Synthes on stem cell approach for degenerated tendons, ligaments

Issue: February 2017

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Orthocell Limited announced a research collaboration agreement with DePuy Synthes Products Inc., part of the Johnson & Johnson Family of Companies, on its Ortho-ATI stem cell approach to regenerate degenerated tendons and ligaments. According to a press release, the partnership was facilitated by Johnson & Johnson Innovation.

Ortho-ATI is a non-surgical approach to treat chronic resistant tendon injuries that significantly impact activities of daily living. Ortho-ATI is offered in Australia and New Zealand for patients who have failed conservative treatment options and have ongoing symptoms. A collaborative, multicenter study on the approach is set to begin in the first quarter of 2017.

“This is [an] exciting partnership in the continued development of Ortho-ATI and provides significant external validation of this globally relevant technology,” Paul Anderson, managing director, said in the release.

Reference:

www.orthocell.com.au/